BamSEC and AlphaSense Join Forces
Learn More

Kairos Pharma Ltd. – Material Contracts

NYSE American: KAPA    
Share price (7/2/26): $0.37    
Market cap (7/2/26): $7.924 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 26 pages Material contract
12/34/56
EX-10.69
from 10-K 5 pages Material contract
12/34/56
EX-10.1
from 8-K 5 pages Binding Term Sheet for Proposed Asset Acquisition Between Kairos Pharma, Ltd. (KAPA) and Celyn Therapeutics, Inc
12/34/56
EX-10.3
from 10-Q 23 pages Material contract
12/34/56
EX-10.1
from 8-K 5 pages Restricted Stock Unit Grant Agreement Kairos Pharma, Ltd
12/34/56
EX-10.2
from 8-K 2 pages Novation of License Agreement
12/34/56
EX-10.1
from 8-K 3 pages Novation of License Agreements
12/34/56
EX-10.3
from 8-K 11 pages Placement Agent and Advisory Services Agreement
12/34/56
EX-10.1
from 8-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 4 pages Kairos Pharma, Ltd. Lock-Up Agreement
12/34/56
EX-10.2
from 8-K 24 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 4 pages December 10, 2024 Mr. Rahul Singhvi 38 Columbine Road Newton, Ma 02459 Re: Director Offer Letter Dear Mr. Rahul Singhvi
12/34/56
EX-10.15
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.14
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.13
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.12
from 10-Q 4 pages Amendment to Employment Agreement
12/34/56
EX-10.11
from 10-Q 3 pages Fourth Amendment to Exclusive License Agreement
12/34/56
EX-10.10
from 10-Q 3 pages Third Amendment to Exclusive License Agreement
12/34/56
EX-10.9
from 10-Q 3 pages Third Amendment to Exclusive License Agreement
12/34/56